Trisenox and hypokalaemia Patient Reports February 13, 2012

Trisenox Side Effects Report #4697685-1
Trisenox side effect was reported by a Physician from on June 03, 2005. Female patient, 57 years of age, weighting 153.0 lb, was diagnosed with multiple myeloma  and was treated with Trisenox. After drug was administered, patient experienced the following side effects: hypokalaemia, lobar pneumonia, proteinuria. Trisenox dosage: 17.2 MG (17.2 MG, UNK), INTRAVENOUS. During the same period patient was treated with BORTEZOMIB, ASCORBIC ACID, AREDIA, ATIVAN, NEURONTIN. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5047197-0
Trisenox side effect was reported by a Physician from JAPAN on June 21, 2006. Female patient, 84 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, disseminated intravascular coagulation, haemoglobin decreased, hypokalaemia, malignant neoplasm progression, platelet count decreased, renal failure, respiratory failure. Trisenox dosage: 4.1 MG QD, INTRAVENOUS DRIP. During the same period patient was treated with FUROSEMIDE, MEXILETINE HYDROCHLORIDE, NIFEDIPINE, NIZATIDINE, INSULIN. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5125022-7
Trisenox side effect was reported by a Physician from JAPAN on Sept 26, 2006. Female patient, 84 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: hypokalaemia, white blood cell count decreased. Trisenox dosage: 7.755 MG QD INTRAVENOUS DRIP. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5022383-4
Trisenox side effect was reported by a Physician from JAPAN on May 30, 2006. Female patient, 84 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, hypokalaemia, platelet count decreased, white blood cell count decreased. Trisenox dosage: 4.1 MG QD INTRAVENOUS DRIP. During the same period patient was treated with FUROSEMIDE, MEXILETINE HYDROCHLORIDE, NIFEDIPINE, NIZATIDINE, INSULIN. Patient was hospitalized. Patient recovered.


Trisenox Side Effects Report #5029162-2
Trisenox side effect was reported by a Physician from JAPAN on May 31, 2006. Female patient, 84 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia, c-reactive protein increased, haemoglobin decreased, hypokalaemia, malignant neoplasm progression, platelet count decreased, white blood cell count decreased. Trisenox dosage: 4.1 MG QD INTRAVENOUS DRIP. During the same period patient was treated with FUROSEMIDE, MEXILETINE HYDROCHLORIDE, NIFEDIPINE, NIZATIDINE, INSULIN. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #6115920-X
Trisenox side effect was reported by a Physician from JAPAN on Feb 27, 2009. Female patient, 81 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: cholecystitis, disseminated intravascular coagulation, hyperkalaemia, hypokalaemia, leukocytosis. Trisenox dosage: 6.225 MG QD INTRAVENOUS DRIP. During the same period patient was treated with IDARUBICIN HYDROCHLORIDE, PAZUFLOXACIN MESILATE, IMIPENEM AND CILASTATIN, MICAFUNGIN, CIPROFLOXACIN, TEICOPLANIN. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #4752552-X
Trisenox side effect was reported by a Physician from JAPAN on Aug 04, 2005. Male patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase decreased, hepatic function abnormal, hypokalaemia. Trisenox dosage: 6 MG (6 MG) IVI. During the same period patient was treated with BIAPENEM, VANCOMYCIN, CLINDAMYCIN, CEFTAZIDIME, ALLOPURINOL, TOSUFLOXACIN, FLUCONAZOLE, FAMOTIDINE. Patient recovered.

Trisenox Side Effects Report #4781090-3
Trisenox side effect was reported by a Physician from JAPAN on Sept 07, 2005. Male patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, condition aggravated, gamma-glutamyltransferase increased, hepatic function abnormal, hypokalaemia. Trisenox dosage: 6 MG (6 MG, IVI). During the same period patient was treated with BIAPENEM, VANCOMYCIN, CLINDAMYCIN, CEFTAZIDIME, ALLOPURINOL, TOSUFOXACIN, FLUCONAZOLE, FAMOTIDINE. Patient recovered.

Trisenox Side Effects Report #4950882-X
Trisenox side effect was reported by a Physician from JAPAN on Mar 01, 2006. Male patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased, hepatic function abnormal, hypokalaemia. Trisenox dosage: 6.6 MG QD INTRAVENOUS DRIP. During the same period patient was treated with BIAPENEM, TOSUFLOXACIN TOSILATE, FLUCONAZOLE, FAMOTIDINE. Patient recovered.


Trisenox Side Effects Report #6065662-4
Trisenox side effect was reported by a Physician from JAPAN on Jan 19, 2009. Female patient, 67 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: cytomegalovirus test positive, dialysis , disease progression, electrocardiogram qt prolonged, hypokalaemia, hypomagnesaemia, intestinal obstruction, renal failure. Trisenox dosage: 5.85 MG QD INTRAVENOUS DRIP. During the same period patient was treated with POTASSIUM, MAGNESIUM. Patient was hospitalized and became disabled. Patient recovered.

Trisenox Side Effects Report #5397293-3
Trisenox side effect was reported by a Physician from JAPAN on July 09, 2007. Female patient, 65 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood lactate dehydrogenase increased, cerebral haemorrhage, disseminated intravascular coagulation, hypokalaemia, leukocytosis. Trisenox dosage: 8.75 MG QD INTRAVENOUS DRIP. During the same period patient was treated with IDARUBICIN, DANAPAROID. Patient died on 04/28/2007.

Trisenox Side Effects Report #5102981-X
Trisenox side effect was reported by a Physician from JAPAN on Aug 23, 2006. Male patient, 39 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, electrocardiogram qt corrected interval prolonged, hepatic function abnormal, hypernatraemia, hypokalaemia, white blood cell count decreased. Trisenox dosage: 10.98 MG QD INTRAVENOUS DRIP. During the same period patient was treated with CYTARABINE, METHOTREXATE, DEXAMETHASONE PHOSPHATE, ELECTROLYTE SOLUTION, RANITIDINE HYDROCHLORIDE. Patient recovered.

Trisenox Side Effects Report #5281885-6
Trisenox side effect was reported by a Physician from JAPAN on Mar 12, 2007. Female patient, 32 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: electrocardiogram qt corrected interval prolonged, electrocardiogram qt prolonged, hypokalaemia, pancytopenia. Trisenox dosage: 8.85 MG QD INTRAVENOUS DRIP. During the same period patient was treated with CEFDINIR, ETIZOLAM, FEXOFENADINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, ZOLPIDEM TARTRATE, GEFARNATE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5497267-8
Trisenox side effect was reported by a Physician from JAPAN on Oct 10, 2007. Female patient, 27 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia differentiation syndrome, alanine aminotransferase increased, aspartate aminotransferase increased, electrocardiogram qt prolonged, haemoglobin decreased, hepatic function abnormal, hypokalaemia, leukocytosis, platelet count decreased. Trisenox dosage: 7.8 MG QD INTRAVENOUS DRIP. During the same period patient was treated with ELECTROLYTE, IDARUBICIN, PANIPENEM, AMIKACIN SULPHATE, MICAFUNGIN, ABREKACIN SULPHATE, MEROPENEM HYDRATE. Patient recovered.


Trisenox Side Effects Report #5525457-4
Trisenox side effect was reported by a Physician from JAPAN on Nov 05, 2007. Female patient, 27 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia differentiation syndrome, alanine aminotransferase increased, aspartate aminotransferase increased, electrocardiogram qt prolonged, haemoglobin decreased, hepatic function abnormal, hypokalaemia, leukocytosis, platelet count decreased. Trisenox dosage: 7.8 MG QD INTRAVENOUS DRIP. During the same period patient was treated with IDARUBICIN, PANIPENEM, AMIKACIN SULPHATE, MICAFUNGIN, ARBEKACIN SULPHATE, MEROPENEM HYDRATE. Patient recovered.

Trisenox Side Effects Report #6012726-7
Trisenox side effect was reported by a Physician from JAPAN on Aug 08, 2008. Female patient was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: cytomegalovirus infection , electrocardiogram qt prolonged, hypokalaemia, hypomagnesaemia, intestinal obstruction. Trisenox dosage: 5.85 MG QD INTRAVENOUS DRIP. During the same period patient was treated with POTASSIUM CHLORIDE, MAGNESIUM. Patient was hospitalized and became disabled. Patient recovered.